Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 20/20 | 0.66 |
| ▸ | ITGAV | P06756 | 20/20 | 0.66 |
| ▸ | ITGB6 | P18564 | 11/20 | 0.55 |
| ▸ | ITGB5 | P18084 | 9/20 | 0.55 |
| ▸ | ITGB8 | P26012 | 8/20 | 0.55 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.54 |
| ▸ | ITGB1 | P05556 | 7/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2905606 | 0.91 | ITGB3 (0.78) | ITGB3ITGAVITGB6ITGB5ITGB8 | |
| SCHEMBL2925397 | 0.90 | ITGB3 (0.77) | ITGB3ITGAVITGB6ITGB5ITGB8 | |
| SCHEMBL2925931 | 0.89 | ITGB3 (0.84) | ITGB3ITGAVITGB6ITGB5ITGB8 | |
| SCHEMBL8344488 | 0.88 | ITGB3 (0.62) | ITGB3ITGAVITGB6ITGB5ITGB8 | |
| SCHEMBL2923399 | 0.83 | ITGB3 (0.67) | ITGB3ITGAVITGB6ITGB5ITGB8 | |
| SCHEMBL2908811 | 0.82 | ITGB3 (0.73) | ITGB3ITGAVITGB5ITGA2BITGB1 | |
| SCHEMBL2917750 | 0.81 | ITGB3 (0.91) | ITGB3ITGAVITGB6ITGB5ITGB8 | |
| SCHEMBL2925336 | 0.81 | ITGB3 (0.64) | ITGB3ITGAVITGB6ITGB5ITGB8 | |
| SCHEMBL2898359 | 0.80 | ITGB3 (0.70) | ITGB3ITGAVITGB6ITGB5ITGB8 | |
| SCHEMBL2906746 | 0.80 | ITGAV (0.69) | ITGB3ITGAVITGB6ITGB5ITGB8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2628727-A2 | Biaryl PDE4 inhibitors for treating pulmonary and cardiovascular disorders | Decode Genetics EHF (IS) | 2013-08-21 | — | — | EP | claimed |
| US-20120213758-A1 | BIARYL PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS | DeCODE Genetics enf (IS) | 2012-08-23 | — | — | US | claimed |
| US-20120207729-A1 | SUBSTITUTED BENZOAZOLE PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS | DECODE GENETICS EHF (IS) | 2012-08-16 | — | — | US | claimed |
| EP-2225216-A1 | SUBSTITUTED BENZOAZOLE PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS | Decode Genetics EHF (IS) | 2010-09-08 | — | — | EP | claimed |
| EP-2222639-A1 | BIARYL PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS | Decode Genetics EHF (IS) | 2010-09-01 | — | — | EP | claimed |
| EP-2217569-A1 | ENANTIOSELECTIVE PROCESS FOR PREPARING A SUBSTITUTED ALKANOIC ACID | Janssen Pharmaceutica N.V. (BE) | 2010-08-18 | — | — | EP | claimed |
| WO-2009067618-A1 | SUBSTITUTED BENZOAZOLE PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS | DECODE GENETICS EHF (IS) | 2009-05-28 | — | — | WO | claimed |
| US-20090136473-A1 | BIARYL PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS | DECODE GENETICS EHF (IS) | 2009-05-28 | — | — | US | claimed |
| WO-2009067621-A1 | BIARYL PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS | DECODE GENETICS EHF (IS) | 2009-05-28 | — | — | WO | claimed |
| US-20090130076-A1 | SUBSTITUTED BENZOAZOLE PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS | DECODE GENETICS EHF (IS) | 2009-05-21 | — | — | US | claimed |
| US-20090124804-A1 | Enantioselective process for preparing a substituted alkanoic acid | JANSSEN PHARMACEUTICA NV (BE) | 2009-05-14 | — | — | US | claimed |
| WO-2009058314-A1 | ENANTIOSELECTIVE PROCESS FOR PREPARING A SUBSTITUTED ALKANOIC ACID | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-05-07 | — | — | WO | claimed |
| US-20140275553-A1 | SUBSTITUTED BENZOAZOLE PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS | DECODE GENETICS EHF (IS) | 2014-09-18 | — | — | US | disclosed |
| EP-2217569-B1 | ENANTIOSELECTIVE PROCESS FOR PREPARING A SUBSTITUTED ALKANOIC ACID | JANSSEN PHARMACEUTICA NV (BE) | 2014-04-16 | — | — | EP | disclosed |
| US-8680278-B2 | Enantioselective process for preparing a substituted alkanoic acid | JANSSEN PHARMACEUTICA NV (BE) | 2014-03-25 | — | — | US | disclosed |
| EP-2628727-A2 | Biaryl PDE4 inhibitors for treating pulmonary and cardiovascular disorders | Decode Genetics EHF (IS) | 2013-08-21 | — | — | EP | disclosed |
| US-20090124804-A1 | Enantioselective process for preparing a substituted alkanoic acid | JANSSEN PHARMACEUTICA NV (BE) | 2009-05-14 | — | — | US | disclosed |
| WO-2009058314-A1 | ENANTIOSELECTIVE PROCESS FOR PREPARING A SUBSTITUTED ALKANOIC ACID | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-05-07 | — | — | WO | disclosed |
| US-20080058359-A1 | Piperidinyl compounds that selectively bind integrins | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-03-06 | — | — | US | disclosed |
| US-20080058359-A1 | Piperidinyl compounds that selectively bind integrins | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058359-A1 | Piperidinyl compounds that selectively bind integrins | ITGB3, ITGAV, ITGA2B | ITGB3 1/4885ITGAV 2/4885ITGB6 17/4885 |
| US-20090136473-A1 | BIARYL PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS | PDE4A, PDE4B, PDE3B | ITGB3 2503/4885ITGAV 3075/4885ITGB6 3585/4885 |
| US-20090130076-A1 | SUBSTITUTED BENZOAZOLE PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS | PDE3B, PDE4B, PDE4A | ITGB3 2569/4885ITGAV 4181/4885ITGB6 3879/4885 |
| US-20120207729-A1 | SUBSTITUTED BENZOAZOLE PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS | PDE3B, PDE4B, PDE4A | ITGB3 2569/4885ITGAV 4181/4885ITGB6 3879/4885 |
| US-20140275553-A1 | SUBSTITUTED BENZOAZOLE PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS | PDE3B, PDE4B, PDE4A | ITGB3 2569/4885ITGAV 4181/4885ITGB6 3879/4885 |
| US-20090124804-A1 | Enantioselective process for preparing a substituted alkanoic acid | ITGA5, ITGA1, ITGB5 | ITGB3 13/4885ITGAV 8/4885ITGB6 11/4885 |
| US-20120213758-A1 | BIARYL PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS | PDE4A, PDE4B, PDE3B | ITGB3 2503/4885ITGAV 3075/4885ITGB6 3585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.